Category: Press Releases

InnoLife-consortium winning bid of Healthy Living and Active Ageing of the European Institute of Innovation and Technology (EIT)

InnoLife, a consortium of 144 European companies, research institutes and universities, has been selected by the European Institute of Innovation and Technology (EIT) as the Knowledge and Innovation Community (KIC) for EIT Health. With a total volume of EUR 2.1 billion it is one of the largest publicly funded initiatives for health worldwide. EIT Healthpartners, […]

Read More

Alacris Theranostics: ModCellTM system will use the SAP HANA® platform

Berlin, 1st April 2014 – Alacris Theranostics has entered into a project with SAP AG (NYSE: SAP) to use the SAP HANA® platform to enable Alacris’ proprietary ModCell™ system. Using SAP HANA is expected to accelerate the modelling and prediction of drug action by Alacris’ ModCellTM system by a factor of several thousand. This allows […]

Read More

Alacris Theranostics: Announces Illumina CSPro Certification

Alacris Theranostics GmbH announced today that it has successfully completed Illumina CSPro™ certification for next generation sequencing (NGS); gaining entry to an elite global group of Illumina genomics service providers. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide. Illumina CSPro is the collaborative service provider partnership dedicated to […]

Read More

Alacris Theranostics enters agreement with GSK to use ModCellTM System for early stage cancer research

Berlin, 14th November 2012 – Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris’ proprietary ModCell™ System, developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris, for drug stratification using data from early stage cancer drug discovery at GSK. GSK will provide to Alacris pre-clinical biology […]

Read More

QIAGEN to acquire stake in Alacris

QIAGEN has signed an agreement for the acquisition of  a strategic stake in Alacris Theranostics GmbH, a German start-up company using the novel technology ModCellTM to develop individualized cancer treatment strategies based upon a patient’s genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.  The […]

Read More